Disease · MONDO_0000607
Targets154
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 20 of 154
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HDAC1 | Histone deacetylase | 5 | Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/3065 | Drugs and targets |
| HDAC2 | Histone deacetylase | 5 | Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/3066 | Drugs and targets |
| HDAC3 | Histone deacetylase | 5 | Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/8841 | Drugs and targets |
| HDAC6 | Histone deacetylase | 5 | Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/10013 | Drugs and targets |
| HDAC10 | Histone deacetylase | 4 | Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/83933 | Drugs and targets |
| HDAC11 | Histone deacetylase | 4 | Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/79885 | Drugs and targets |
| HDAC4 | Histone deacetylase | 4 | Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/9759 | Drugs and targets |
| HDAC5 | Histone deacetylase | 4 | Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/10014 | Drugs and targets |
| HDAC7 | Histone deacetylase | 4 | Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/51564 | Drugs and targets |
| HDAC8 | Histone deacetylase | 4 | Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/55869 | Drugs and targets |
| HDAC9 | Histone deacetylase | 4 | Histone deacetylase inhibitor | Approval | https://conductscience.org/library/genes/9734 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 4 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| ADRM1 | 26S proteasome | 3 | 26S proteasome inhibitor | Phase 3 | https://conductscience.org/library/genes/11047 | Drugs and targets |
| EEF2 | Elongation factor 2 | 3 | Elongation factor 2 inhibitor | Approval | https://conductscience.org/library/genes/1938 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| PIK3CD | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | 3 | PI3-kinase p110-delta subunit inhibitor | Phase 1/2 | https://conductscience.org/library/genes/5293 | Drugs and targets |
| PSMA1 | 26S proteasome | 3 | 26S proteasome inhibitor | Phase 3 | https://conductscience.org/library/genes/5682 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000607/targets